Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objectives of this study are to compare in nucleoside treatment-naïve subjects, the
efficacy and safety of clevudine 30 mg once daily versus adefovir 10 mg once daily, each as
monotherapy, for 48 weeks, 72 weeks, and 96 weeks.